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plan, with the smaller tumour dimensions making them eli-
gible for eye-preserving therapy.
Conclusion High-field ocular MRI can yield a more accu-
rate measurement of the tumour dimensions than conven-
tional ultrasound, which can result in significant changes in 
the prescribed treatment.
Keywords Magnetic resonance imaging (MRI) · Uveal 
melanoma · Ophthalmology · Eye · Ultrasound
Introduction
The advantages of ultra-high-field human MRI com-
pared to lower clinical fields primarily revolve around the 
increased signal-to-noise ratio (SNR), which can be used to 
increase the spatial resolution in a given imaging time. One 
of the aims of translating ultra-high-field MRI into true 
clinical applications is to determine which types of appli-
cation require a higher spatial resolution than is currently 
achieved at clinical field strengths of 1.5 and 3 T. The major 
challenges include the increase in tissue T1 relaxation times 
and decreased T1-tissue contrast, the (in general) decreased 
T2 relaxation times, and the increased sensitivity to differ-
ences in magnetic susceptibility. This means that clinical 
scanning protocols from lower fields must be re-optimised 
in terms of the different relaxation times. A recent paper 
provided a comprehensive overview of the current clinical 
applications of ultra-high-field MRI [1].
One topic that was not specifically covered in this par-
ticular review was ophthalmic MRI. The potential advan-
tages for clinical use revolve directly around the increased 
spatial resolution achievable within acceptable scan times 
(since short scans must be used to minimise eye-motion-
induced image artefacts): this increased spatial resolution 
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is key for identifying small pathologies within the eye. In 
recent years, MRI has become a promising new diagnos-
tic imaging modality in ophthalmology, a discipline that 
relies mainly on optical imaging techniques [2–9]. How-
ever, eye motion results in a high degree of image artefacts, 
which interfere with the diagnosis. By employing dedicated 
scan paradigms such as cued blinking [10], high-resolu-
tion, essentially motion-free MR images of the eye can be 
obtained. Compared to the conventional optical measure-
ment techniques prevalent in ophthalmology departments, 
MRI has two key advantages that allow it to provide addi-
tional valuable clinical information. First, unlike optical 
imaging methods, MRI is not affected by refraction, which 
can lead to systematic geometrical measurement errors. For 
this reason, ocular MRI is being used by many different 
groups to generate geometrical eye models to study ocular 
conditions such as myopia [5, 11–14]. Second, the ability 
of MRI to image opaque tissues such as ocular tumours and 
optic nerve pathologies offers the potential to improve the 
diagnosis of patients suffering from these diseases [3, 6, 9, 
15].
Uveal melanoma is the most common primary intraocu-
lar malignant tumour in adults [16–20]. In the past, enucle-
ation (surgical removal of the eye) was the main treatment, 
but in the last 10 years various eye- and vision-saving treat-
ments have become available, including ruthenium plaque 
brachytherapy and proton beam radiation therapy [21]. The 
optimal treatment is mainly determined by the location 
and size of the tumour. Ruthenium plaque brachytherapy, 
for example, spares most of the healthy surrounding tissue, 
resulting in optimal preservation of visual function, but is 
only suitable for small to medium sized tumours that are 
not proximate to the optic nerve. For larger tumours exter-
nal beam therapy can be prescribed, but in a number of 
cases the eye needs to be removed.
For a patient to be eligible for ruthenium plaque brachy-
therapy the maximum distance between the outside of the 
sclera, where the plaque is located, and the tumour is 7 mm 
[22]. Clinically, the extent of the tumour is primarily deter-
mined using 10 MHz B-scan ultrasonography, as shown in 
Fig. 1, in which an ultrasound transducer is manually posi-
tioned to acquire a two-dimensional image. To measure the 
prominence of the tumour correctly, the transducer needs to 
be positioned perpendicular to the tumour, which is often 
not possible because of the surrounding tissue, e.g. the 
nose. These oblique cuts through the tumour result in an 
over-estimation of the tumour size, with the degree of over-
estimation being patient/tumour specific, meaning that no 
simple correction algorithm can be applied. Furthermore, 
since ultrasound only measures two-dimensional cross sec-
tions of the tumour, it can potentially miss the location of 
the maximum tumour size. Recent advances in ocular MRI 
make it possible to image the complete tumour in three 
dimensions, potentially allowing a much better determina-
tion of the maximum tumour prominence. In this article, 
we show the MR data acquired in ten patients with uveal 
melanoma using a custom-built RF coil at 7 T and compare 
the tumour dimensions determined from the MR images 
with those acquired via clinical ultrasound evaluation.
Materials and methods
The patients were admitted to the Department of Ophthal-
mology at the LUMC, and all data were acquired accord-
ing to the Declaration of Helsinki. After the standard clini-
cal evaluations (optical and ultrasound measurements), an 
additional 7-T ocular MRI examination was performed. For 
the ultrasound a probe (Quantel Medical Aviso, Cournon 
d’Auvergne France) was used with a transducer fre-
quency of 10 MHz, an exploration angle of 50°, focus of 
24–26 mm, axial resolution of 200 µm and lateral resolu-
tion of 600 µm (data supplied by the manufacturer). Ultra-
sound images from three representative patients are shown 
in Fig. 1.
The MRI measurements were performed on a Philips 
(Best, The Netherlands) Achieva 7-T whole-body magnet 
[9]. A custom-made dedicated receive eye coil was used 
in combination with a volume transmit coil (Nova Medical 
Inc., Wilmington, MA, USA). In previous research scans 
a three-channel eye-coil array was used: in this design the 
conductive wires of the resonator blocked the view of the 
eye. In the coil used in this study, a single-channel receive 
coil was constructed as this allowed the patient to look 
Fig. 1  B-scan ultrasono-
graphic images of the eyes of 
three patients showing uveal 
melanoma
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through the centre of the coil: furthermore the robustness of 
the coil was improved by construction on a printed circuit 
board and the use of a miniature LC-Balun. Details of the 
coil design are shown in Fig. 2.
To reduce susceptibility artefacts, the affected eye was 
closed with a piece of tape and covered with a piece of wet 
gauze [23]. The patients were instructed to focus with the 
non-affected eye on a Malthusian cross during the scans. 
As the movement of the imaged eye is highly correlated 
with movement of the non-imaged eye, eye blinking of the 
non-imaged eye results in severe motion artefacts. These 
eye-motion artefacts were minimised by the use of a cued-
blinking protocol consisting of a regular break every 3 s, in 
which the scanner was automatically paused and the sub-
jects were visually instructed to blink [10].
MR images were acquired using a 3D inversion recov-
ery turbo gradient echo technique (MP-RAGE) with 
an inversion time of 1280 ms, a shot interval of 3 s, and 
a turbo field echo factor of 92. The TR/TE/tip angle was: 
6.7 ms/3.4 ms/16°. The scan time was 3 min and resulted in 
a spatial resolution of 0.4 × 0.4 × 0.9 mm3 and a field of 
view (FOV) of 40 × 46 × 38 mm3. Two orthogonal recon-
structions were made from this scan, from which additional 
two-dimensional scans were planned with different types of 
contrast. A turbo spin-echo sequence was used to acquire 
four slices of 1 mm thickness with a TR of 2500 ms and an 
echo train length of 10. The scan was performed both with 
and without spectral inversion recovery (SPIR) fat suppres-
sion and had an in-plane resolution of 0.3 × 0.3 mm2. The 
slice gap was adjusted for every patient in order to cover 
the complete tumour, and the scan took slightly more 
than 1 min. Then a 3D spoiled gradient echo with a TR/
TE/tip angle of 10 ms/2.9 ms/6°, a spatial resolution of 
0.5 × 0.5 × 1.0 mm3 and an FOV of 40 × 46 × 38 mm3 
was acquired in 1 min and 16 s. Finally a multi-slice inver-
sion recovery with SPIR fat suppression was acquired with 
an echo-train length of 16, a resolution of 0.3 × 03 mm2 
and a total acquisition time of 3.5 min.
Results
For all patients the MRI scans resulted in motion-free 
images in which the tumour could clearly be delineated, 
representative images are shown in Figs. 3 and 4. The 
inversion recovery based scans (Figs. 3a, b and 4a, d, g) 
show the highest contrast between the tumour and the sur-
rounding vitreous body, and the sclera can be differentiated 
Fig. 2  Schematics and pictures of the single-channel receive eye 
coil. The dimensions of the resonator are 45 × 35 mm2. a Values 
of lumped elements used to tune and impedance match the coil at 
298.1 MHz. b To decouple the cable from the resonator an LC-Balun 
was used because of its stability and small size. c Photograph of the 
coil plus LC-Balun on the 3D printed former. d Mirrors were attached 
to the coil housing to allow the patient to look at a screen positioned 
at the end of the magnet bore
Fig. 3  High-resolution MR images from four patients (the images of 
three additional patients are shown in Fig. 4). The images illustrate 
the wide variety of tumour shapes and locations in UM. a, b Images 
acquired with the 3D MPRAGE sequence, which provides high con-
trast between the tumour and vitreous body. The 3D nature of these 
images allows for an accurate assessment of the tumour dimensions. 
c, d Fat-suppressed 2D spin-echo images show a hypointense sclera, 
allowing to screen for extra-scleral tumour extensions
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from the uveal layer. The three-dimensional nature of this 
scan allows a complete assessment of the spatial extent of 
the tumour. These images, however, show a low contrast 
between the sclera and orbital fat (it should be noted that 
the ultrasound images in Fig. 1 show an even poorer con-
trast between these tissues). For the assessment of extra-
scleral extensions of the tumour, however, a better deline-
ation of the sclera is needed since the boundary between 
the surrounding hypo- and hyperintense layers can be very 
convoluted. To this end, the high-resolution T2-weighted 
multi-slice spin-echo images, shown in Figs. 3d, e and 4b, 
e, f, h, i, were acquired, which clearly show the hypoin-
tense sclera. Finally, Fig. 4c shows the images from the 3D 
spoiled gradient echo sequence. Although this sequence 
yields a lower SNR than the other sequence types, it does 
have high intra-tumour contrast. The hypointense region in 
the centre of the tumour of Fig. 4a–c is speculated to be a 
necrotic region rich in melanin. Since the eye of this patient 
did not need to be enucleated, this hypothesis could (fortu-
nately) not be verified by histology.
The maximal prominence of the tumour for each patient 
was assessed on the 3D inversion recovery scan using 
a thee-dimensional viewer. Figure 4 shows the result of 
this assessment for the three representative patients from 
Fig. 1. For patient 1 the MR images showed a prominence 
of 6.2 mm, for patient 2 a prominence of 9.2 mm and for 
patient 3 a prominence of 12.2 mm. The results for all 
patients are summarised in Fig. 5. For two patients the MRI 
showed the same tumour prominence as the ultrasound. For 
five patients, including patients 1 and 2 from Figs. 1 and 3, 
Fig. 4  High-resolution images from the three patients from Fig. 1 
[patient 1 (a, b, c), patient 2 (d, e, f) and patient 3 (g, h, i)]. The 
tumour prominence (green line) was measured on the images 
acquired with the 3D MPRAGE sequence (a, d, g). (b, e, h, i) 2D 
spin-echo acquisitions measured perpendicular to the tumour. c A 
3D spoiled gradient FFE shows a hypointense structure within the 
tumour. i A fat-suppressed inversion recovery sequence can be used 
to screen for tumour infiltrations through the sclera
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the MRI revealed a smaller tumour prominence compared 
to the ultrasound. In three cases, including patient 3, the 
MR images showed a larger tumour. The tumours of these 
patients were relatively large (>10 mm) and consisted of 
multiple lobes.
Discussion
For 80 % of the patients the MRI-based 3D evaluation 
of the tumour prominence resulted in a different tumour 
prominence compared to the ultrasound. For some of the 
large tumours, which consisted of multiple lobes, the MRI 
showed an up to 1.6 mm larger tumour. As the eyes of 
these patients were not eligible for eye-preserving therapy, 
this did not have any influence on the proposed treatment. 
In five of the ten patients, however, the MRI revealed an 
up to 1.5 mm smaller tumour. For two of these patients 
(including patient 1 from Figs. 1 and 3), this resulted in 
a substantial change in treatment plan. For these patients 
the original ultrasound measurements showed a tumour 
with a prominence slightly too large for ruthenium plaque 
therapy, which for this patient would result in the enu-
cleation of the eye. The MRI, however, showed a slightly 
smaller tumour that would still be eligible for ruthenium 
plaque therapy, which meant that the eye could be spared. 
Because of the uncertainties of the ultrasound, especially 
the potential oblique cuts through the tumour, the final 
decision was based on the MR images, and ruthenium 
plaque therapy was offered. (The total radiation dose deliv-
ered by a ruthenium plaque decreases as the distance from 
the plaque increases; therefore, an accurate determination 
of the maximum distance between the outer sclera and 
tumour is needed to select which patients are eligible for 
this treatment.)
As small millimetre-size differences in tumour promi-
nence can result in significant changes in the treatment, 
accurate length measurements are essential to assess the 
optimal treatment. Although higher field MRI enables an 
increased spatial resolution, magnetic susceptibility effects 
are greater, which could potentially distort the images. 
The application of wet gauze to the imaged eye effectively 
shifts the air/tissue interface much further away from the 
eye. Small air bubbles can sometimes be present below the 
eyelid and can produce very local distortions in the image, 
but as the tumours are located posteriorly the image of the 
tumour itself is not affected. Further evidence that high-
field MRI gives accurate ocular length measurements was 
provided in previous work that showed a high degree of 
agreement, <1 % difference, compared to the gold stand-
ard of optical biometry [5]. Overall, all of these considera-
tions indicated a high accuracy of MRI-based geometrical 
measurements in the eye. Furthermore, as the MR images 
provide a higher contrast between the sclera and orbital fat 
than ultrasound, MRI is able to provide a better delineation 
of the tumour boundaries, justifying an MRI-based deter-
mination of the optimal treatment.
To assess the reproducibility of the measurements, both 
the ultrasound and MR images were retrospectively evalu-
ated by two additional independent observers. The MRI 
showed a slightly lower difference between the measure-
ments compared to the ultrasound, an average SD of 0.22 
and 0.32 mm respectively. Clinically, the variability of the 
ultrasound evaluation will be significantly higher as the 
measurement is very dependent on the orientation of the 
ultrasound transducer. A comprehensive study by Char 
et al. [24] showed a 0.60-mm interobserver variability in 
the ultrasound evaluation. As the MRI acquires a full 3D 
description of the tumour, it provides the possibility to 
make a cross section in every direction, removing this sig-
nificant source of variability. Furthermore, the MRI allows 
for a retrospective verification of the orientation in which 
the measurement was taken, which cannot be done with the 
2D ultrasound.
In addition to the described diagnostic value of the addi-
tional MRI scans, the evaluation of these patients revealed 
two other potential benefits of MRI compared to ultra-
sound. First, the full three-dimensional data on the tumour 
geometry can be used for more precise planning for the dif-
ferent forms of external beam radiotherapy of uveal mela-
noma: this is currently based on two-dimensional fundus 
photography and ultrasound images. Second, the high intra-
tumour contrast compared to ultrasound potentially enables 
a better determination of the tumour response to therapy. 
Fig. 5  Comparison between the ultrasound and MRI measurements 
of the tumour prominence of ten uveal melanoma patients. In 5 
of these patients the 3D MRI evaluation revealed a smaller tumour 
compared to the 2D ultrasound images. In the three patients with a 
large and complexly shaped tumour, the MRI showed a larger tumour 
prominence
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Currently, only changes in the outer tumour dimensions 
can be monitored, which are known to change after the full 
course of therapy is finished. The higher contrast of MRI 
could show tumour response at an earlier stage, enabling a 
more patient-specific treatment.
Conclusion
This work has shown the diagnostic potential of ultra-
high-field ocular MRI for uveal melanoma. In eight of the 
ten patients presented, the three-dimensional MR images 
provided a better measurement of the tumour dimensions 
compared to conventional ultrasound. For two of these 
patients this resulted in a significant change in treatment. 
The ultrasound suggested the tumour was too large for 
ruthenium plaque brachytherapy, in which case removal 
of the eye would have been considered. The three-dimen-
sional MRI data, however, enabled a more precise meas-
urement of the tumour dimensions, resulting in a slightly 
lower tumour prominence, which is still feasible for 
brachytherapy. This resulted in the preservation of these 
particular patient’s eye.
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